Bare Financial Services
NBIX icon

Bare Financial Services’s Neurocrine Biosciences NBIX Stock Holding History

Bare Financial Services’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$6.67K Buy
47
+8
+21% +$1.29K ﹤0.01% 792
2026
Q2 		$6.57K Buy
39
+2
+5% +$297 ﹤0.01% 754
2026
Q1 		$4.87K Buy
37
+1
+3% +$133 ﹤0.01% 656
2025
Q4 		$5.11K Buy
36
+1
+3% +$145 ﹤0.01% 532
2025
Q3 		$4.91K Buy
35
+5
+17% +$677 ﹤0.01% 542
2025
Q2 		$3.77K Buy
+30
New +$3.44K ﹤0.01% 609

Other funds holding NBIX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $61B AUM 26.91% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 24.61% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return
KBC Group
KBC Group Brussels, Belgium $47.9B AUM 37.61% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return

Bare Financial Services's NBIX Position: Q3 2026 in Review

Bare Financial Services increased its Neurocrine Biosciences (NBIX) stake by 21% in Q3 2026, buying an estimated $1.29K and bringing the position to 47 shares worth $6.67K. The position accounts for ﹤0.01% of the portfolio, ranked #792.

Bare Financial Services first reported a position in NBIX in Q2 2025 and has held it in 6 quarters since. 396 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • Bare Financial Services held 47 shares of Neurocrine Biosciences worth $6.67K as of Q3 2026.
  • Bare Financial Services bought 8 Neurocrine Biosciences shares in Q3 2026, an estimated $1.29K.
  • Neurocrine Biosciences made up ﹤0.01% of Bare Financial Services's portfolio in Q3 2026, its #792 holding.
  • Bare Financial Services first reported a position in Neurocrine Biosciences in Q2 2025 and has held it in 6 quarters since.
  • 396 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on Bare Financial Services's 13F filing for Q3 2026, filed 4 Nov 2026.